Limits...
Adalimumab (humira™) in ophthalmology: a review of the literature.

Neri P, Lettieri M, Fortuna C, Zucchi M, Manoni M, Celani S, Giovannini A - Middle East Afr J Ophthalmol (2010)

Bottom Line: Adalimumab has been successfully used for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis.Albeit no direct comparison with other biologics has been done, and adalimumab seems to be equivalent to the other anti-TNF-α, the switching to adalimumab can offer a better uveitic control.Adalimumab is a promising drug for the treatment of uveitis, even though further studies are needed on its application as a primary therapy in uveitis.

View Article: PubMed Central - PubMed

Affiliation: The Eye Clinic-Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi, Ancona, Italy.

ABSTRACT
Tumor Necrosis Factor alpha (TNF-α) is a pleiotropic cytokine which plays a primary role in the induction of inflammation in autoimmune diseases. The newest anti-TNF-α agent is adalimumab (Humira, Abbott Pharmaceutical Inc.), a human-derived antibody. This review summarizes the characteristics of adalimumab, highlighting its clinical use in systemic and ocular inflammatory disorders, and the possible therapeutic strategies. Adalimumab has been successfully used for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis. More recently, adalimumab has shown promising qualities in controlling intraocular inflammations, even though this has been used prevalently as a rescue therapy for unresponsive cases. This biologic agent was also used in pediatric cases, showing a good safety and efficacy profile. Albeit no direct comparison with other biologics has been done, and adalimumab seems to be equivalent to the other anti-TNF-α, the switching to adalimumab can offer a better uveitic control. Adalimumab is a promising drug for the treatment of uveitis, even though further studies are needed on its application as a primary therapy in uveitis.

No MeSH data available.


Related in: MedlinePlus

Fluorescein angiography of a patient affected by bilateral panuveitis with bilateral cystoid macular edema (A, B). The patients did not respond to the previous treatment with steroids, cyclosporine A, and azathioprine. After the introduction of adalimumab, the patient had a dramatic improvement, resolving the intraocular inflammation and the associated CME (C, D)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2991444&req=5

Figure 0001: Fluorescein angiography of a patient affected by bilateral panuveitis with bilateral cystoid macular edema (A, B). The patients did not respond to the previous treatment with steroids, cyclosporine A, and azathioprine. After the introduction of adalimumab, the patient had a dramatic improvement, resolving the intraocular inflammation and the associated CME (C, D)

Mentions: Another potential application of adalimumab in ocular inflammations can be in idiopathic panuveitis associated with CME, unresponsive to the traditional immune suppressive treatment [Figure 1]. In our center at the ocular immunology unit of the Ospedali Riuniti Umberto I-GM Lancisi-G Salesi of Ancona, Italy, we have treated successfully two patients with active bilateral idiopathic panuveitis associated with CME (unpublished data) who were unresponsive to previous treatments with traditional immune suppressive agents. At last follow-up, both patients had improved the best-corrected visual acuity (BCVA) and a fully controlled ocular inflammation [Figure 2]. In addition, the considered patients did not show signs of CME up to the last follow-up [Figure 3], which was not inferior to 9-month in both patients.


Adalimumab (humira™) in ophthalmology: a review of the literature.

Neri P, Lettieri M, Fortuna C, Zucchi M, Manoni M, Celani S, Giovannini A - Middle East Afr J Ophthalmol (2010)

Fluorescein angiography of a patient affected by bilateral panuveitis with bilateral cystoid macular edema (A, B). The patients did not respond to the previous treatment with steroids, cyclosporine A, and azathioprine. After the introduction of adalimumab, the patient had a dramatic improvement, resolving the intraocular inflammation and the associated CME (C, D)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2991444&req=5

Figure 0001: Fluorescein angiography of a patient affected by bilateral panuveitis with bilateral cystoid macular edema (A, B). The patients did not respond to the previous treatment with steroids, cyclosporine A, and azathioprine. After the introduction of adalimumab, the patient had a dramatic improvement, resolving the intraocular inflammation and the associated CME (C, D)
Mentions: Another potential application of adalimumab in ocular inflammations can be in idiopathic panuveitis associated with CME, unresponsive to the traditional immune suppressive treatment [Figure 1]. In our center at the ocular immunology unit of the Ospedali Riuniti Umberto I-GM Lancisi-G Salesi of Ancona, Italy, we have treated successfully two patients with active bilateral idiopathic panuveitis associated with CME (unpublished data) who were unresponsive to previous treatments with traditional immune suppressive agents. At last follow-up, both patients had improved the best-corrected visual acuity (BCVA) and a fully controlled ocular inflammation [Figure 2]. In addition, the considered patients did not show signs of CME up to the last follow-up [Figure 3], which was not inferior to 9-month in both patients.

Bottom Line: Adalimumab has been successfully used for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis.Albeit no direct comparison with other biologics has been done, and adalimumab seems to be equivalent to the other anti-TNF-α, the switching to adalimumab can offer a better uveitic control.Adalimumab is a promising drug for the treatment of uveitis, even though further studies are needed on its application as a primary therapy in uveitis.

View Article: PubMed Central - PubMed

Affiliation: The Eye Clinic-Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi, Ancona, Italy.

ABSTRACT
Tumor Necrosis Factor alpha (TNF-α) is a pleiotropic cytokine which plays a primary role in the induction of inflammation in autoimmune diseases. The newest anti-TNF-α agent is adalimumab (Humira, Abbott Pharmaceutical Inc.), a human-derived antibody. This review summarizes the characteristics of adalimumab, highlighting its clinical use in systemic and ocular inflammatory disorders, and the possible therapeutic strategies. Adalimumab has been successfully used for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis. More recently, adalimumab has shown promising qualities in controlling intraocular inflammations, even though this has been used prevalently as a rescue therapy for unresponsive cases. This biologic agent was also used in pediatric cases, showing a good safety and efficacy profile. Albeit no direct comparison with other biologics has been done, and adalimumab seems to be equivalent to the other anti-TNF-α, the switching to adalimumab can offer a better uveitic control. Adalimumab is a promising drug for the treatment of uveitis, even though further studies are needed on its application as a primary therapy in uveitis.

No MeSH data available.


Related in: MedlinePlus